Open Access<p>Valproic Acid Addresses Neuroendocrine Differentiation of LNCaP Cells and Maintains Cell Survival</p>
Author(s) -
Francesca Giordano,
Giuseppina Daniela Naimo,
Alessandra Nigro,
Francesco Romeo,
Alessandro Paolì,
Francesca De Amicis,
Adele Vivacqua,
Catia Morelli,
Loredana Mauro,
Maria Luisa Panno
Publication year - 2019
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s229930
Subject(s) - lncap , neuroendocrine differentiation , cancer research , cell growth , prostate cancer , biology , epigenetics , pi3k/akt/mtor pathway , protein kinase b , carcinogenesis , medicine , endocrinology , cancer , signal transduction , microbiology and biotechnology , biochemistry , gene
Neuroendocrine differentiation of prostate cancer, induced by androgen deprivation therapy, is mainly related to advanced disease and poor clinical outcome. Genetic and epigenetic alterations are the key elements of the prostate carcinogenesis. A group of compounds able to induce changes in this sense is inhibitors of histone deacetylase, to which it belongs valproic acid (VPA). In the present paper, we evaluated the role of this molecule on the neuroendocrine differentiation of LNCaP cells together with the effect on proliferation and survival signals.